← Back to patent-cliff list
Axitinib injectable suspension (Clearside Biomedical)
Tier C — Watch / tradeAxitinib injectable suspension (Clearside Biomedical)
Clearside Biomedical Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDGFR-β, VEGFR1, VEGFR2, VEGFR3
Indications (approved)：年龄相关性黄斑变性
Regional status
US
Phase II
2020-12-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Axitinib injectable suspension (Clearside Biomedical)?
Approved indications include: 年龄相关性黄斑变性.
When does the Axitinib injectable suspension (Clearside Biomedical) patent expire?
No public expiry year is available for Axitinib injectable suspension (Clearside Biomedical) yet; this page updates once verified.
How do I get a quote for Axitinib injectable suspension (Clearside Biomedical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06